anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medical engineering. SUBSTANCE: coating has titanium oxide and calcium phosphate compounds taken in known quantitative proportions. Method involves anodizing titanium and its alloys with pulsating current using spark discharge. The process is carried out in saturated solution of hydroxyapatite in phosphoric acid of 5-20% concentration or 3-5 hydroxyapatite suspension which dispersity is less than 100 mcm in the saturated solution. EFFECT: osteoinductive coating causing no suppuration, inflammation, allergic response of bone tissues; improved adhesion to surrounding tissues. 2 cl, 1 tbl
Most health care providers in developing countries know that oral rehydration salts (ORS) are a lifesaving and inexpensive treatment for child diarrhea, yet few prescribe it. This know-do gap has puzzled experts for decades. Using randomized experiments in India, we estimated the extent to which ORS underprescription is driven by perceptions that patients do not want ORS, provider's financial incentives, and ORS stock-outs (out-of-stock events). Patients expressing a preference for ORS increased ORS prescribing by 27 percentage points. Eliminating stock-outs increased ORS provision by 7 percentage points. Removing financial incentives did not affect ORS prescribing on average but did increase ORS prescribing at pharmacies. We estimate that perceptions that patients do not want ORS explain 42% of underprescribing, whereas stock-outs and financial incentives explain only 6 and 5%, respectively.
PURPOSE:An analgesic agent containing a disaccharide derivative. CONSTITUTION:An analgesic obtained by containing a compound expressed by the formula (m, m', n and n' are 6-12; R1, R2, R3 and R4 are OH, H, lower-medium acyloxy; R5 and R6 are H or phosphoric acid) or salt thereof as an active ingredient. The compound expressed by the formula has been considered as promising as a preventing, treating and antitumor agent for diseases (various infectious diseases) caused by immune depression, but has analgesic action not inferior to that of general antipyretic and analgesic agents. Examples of the object diseases include headache, toothache, neuralgia, post-operative pain, cancerous pain, etc. The agent is orally or parenterally administered and the does thereof is 0.1-100mg/adult/day in administering as an injections. EFFECT:This agent has effect on infectious diseases and tumors and is capable of simultaneously treating diseases and pains involved therein.
This will be a prospective, controlled study that will be conducted in the Namutumba district. This district was selected because in a preliminary study, the prevalence of dyspeptic symptoms in this district was found to be 57%. Namutumba District has a population of slightly over 210,000 people. The prevalence of chronic dyspepsia and their associated symptoms will be determined using a questionnaire administered to all willing participants. All participants, regardless of symptoms, will also be offered fecal Hp antigen testing. Participants found to be infected with Hp will be given a 14-day course of antibiotics, per the current Ugandan standards of care, and assessed one month following completion of treatment. Participants with chronic dyspepsia who are negative for Hp will be given daily omeprazole for one month, and their symptoms will be assessed after one month.
The KIU! intervention is a multi-media online HIV prevention program developed specifically for young (18-29 years old) men who have sex with men (MSM) who recently tested HIV negative. Intervention content includes discussions of community involvement, scenarios on hooking-up online, communication skills in relationships (including negotiating safer sex), condom use, HIV knowledge, and HIV/STI risks. Information is presented in various formats like games, animation, and videos to address gaps in HIV knowledge, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors. The intervention is completed across three sessions, done at least 24 hours apart (i.e. at least 3 days), and takes about 2 hours total to complete.
OBJECTIVE: This study aims to audit the adherence of Jordanian medical care staff to the guidelines provided by the Infectious Disease Society of America (IDSA) for managing pediatric patients admitted with suspected cases of meningitis.
METHODS: A retrospective observational study was conducted at Jordan University Hospital (JUH). All pediatric patients admitted to JUH with suspected meningitis between January 1, 2019, and September 30, 2022, who underwent Cerebrospinal Fluid (CSF) and blood culture tests were recruited in this study unless there was a reason for exclusion. The study collected data on the empiric antibiotics prescribed prior to diagnostic cultures and susceptibility results. Additionally, the length of hospital stay and all-cause mortality were observed. The appropriateness of antibiotics prescription before culture results was compared to IDSA guidelines, and an overall adherence rate was calculated.
RESULTS: A total of 332 pediatric patients were included in this study, of whom 12.3% (n = 41) were diagnosed with bacterial meningitis. Among the enrolled pediatric patients, only 27 patients (8.1%) received appropriate treatment adhering to the IDSA guidelines. The remaining 91.9% (n = 305) showed various forms of non-adherence to recommendations. The highest adherence rate was observed for performing CSF culture (n = 330, 99.4%), while the lowest adherence rate was found in selecting the appropriate dose and duration for empiric antibiotics (n = 107, 41.3% and n = 133, 51.0%, respectively).
CONCLUSION: This study revealed a low overall adherence in the management of pediatric patients with meningitis in Jordan. Establishing an antimicrobial stewardship program may improve the outcomes of meningitis infections found in Jordan, and prevent dangerous adverse effects and bacterial resistance.
PURPOSE: Laryngeal dystonia (LD) is a focal dystonia affecting laryngeal musculature with no known etiology or cure. The present study evaluated the sociodemographic and clinical features of patients diagnosed with LD.
MATERIALS AND METHODS: All patients diagnosed with LD at our University Hospital's Ear, Nose, and Throat Department between January 2017 and July 2023 were retrospectively analyzed. The study included 43 patients.
RESULTS: Out of the 43 patients, 19 (44%) were male. At the time of diagnosis, the mean age of the patients was 35.1 years (ranging from 17 to 65 years). The mean elapsed time between the first symptom onset and the first diagnosis was 49.2 months (min. 4 months, max. 240 months). Of the participants, 94% had adductor-type LD. None of the patients had a family history of LD. Of the patients, 9 (20%) experienced a life-altering event or trauma just before the onset of symptoms. All patients who consumed alcohol reported symptom relief with alcohol intake. A total of 67.6% of patients stated that their symptoms were triggered by stress. All of our patients received at least one Botulinum toxin injection, with an average of 2.75 dosages per patient.
CONCLUSION: The gender distribution was approximately equitable between males and females. There was a tendency for men to receive a diagnosis earlier than women following the manifestation of symptoms. A significant number of patients associate the emergence of their symptoms with a stressful event or traumatic experience. This study represents the initial investigation into the sociodemographic characteristics of patients within the Turkish population.
OBJECTIVE: Our aim was to compare the PIK3CA mutation status in matched primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer (BC) to gain insight into the optimization of patient selection and detection time for PIK3CA-targeted therapy.
METHODS: The data were from 3035 patients with BC diagnosed at the Breast Disease Center, Peking University First Hospital, between January 2008 and December 2017. Matched primary and recurrent samples were profiled using amplification-refractory mutation system-polymerase chain reaction covering 11 mutational hotspots in PIK3CA.
RESULTS: PIK3CA mutations were detected in 54.3% primary tumors and 48.6% corresponding recurrences. PIK3CA mutation was detected in 37.5% cases in the locoregional recurrent group and 40.0% of distant metastasis, without a statistical difference. Besides, PIK3CA mutations were concordant in 88.6% of the matched pairs. For patients treated with neoadjuvant chemotherapy, 100% concordance was observed. However, PIK3CA mutation was neither correlated with clinicopathological features nor associated with clinical outcomes.
CONCLUSIONS: Mutations in PIK3CA in HR+/HER2- BC generally progressed to recurrent tumors. The high concordance rate of PIK3CA mutation status between primary tumors and corresponding recurrences suggests that the detection of primary tumors could be a substitute approach when recurrent samples are not easily obtainable.
Pregnant women were vaccinated against tetanus with thestandard application technique.The pain was evaluated with Number rating scale. The pain was evaluated immediately after vaccination and hemodynamic parameters were examined before and after the vaccination. A total of 32 pregnant women completed the study in the standard application group.
PURPOSE:The titled effective biophylactic agent, containing a substance having metallothionein induction ability in human or animal living bodies as an active ingredient and capable of exhibiting inhibitory action on damage of the living bodies by various oxidative invasions. e.g. exposure to radiation, etc. CONSTITUTION:An antioxidant biophylactic agent containing a substance having metallothionein induction ability in human or animal living bodies as an active ingedient. Manganese or a compound thereof, hemolytic streptococci subjected to elimination treatment of streptolysin S production ability, e.g. Streptococcus haemolyticus, and an extract of Coriolus versicolor Quel belonging to the family Polyporacease are particularly preferred for the substance having the metallothionein induction ability. In use, the above-mentioned active ingredient is directly used or mixed with a diluent, excipient, etc., and orally or parenterally administered.
The invention discloses a medicament for treating fractures, which is prepared from the following medicaments in percentage by weight: calcined pyrite, ground beetle, frankincense, myrrh, dragon's blood, raw pinellia tuber, crabshell and catechu. The formula has rigorous compatibility; the calcined pyrite serving as a monarch medicament in a prescription is used for bonesetting and analgesic therapy, and is the key medicament of the bonesetting of orthopedics; the ground beetle is used for the reunion of fractured tendons and bones and is used as a ministerial medicament; the frankincense, the myrrh, the dragon's blood and the catechu are used for promoting blood circulation by removing blood stasis, promoting tissue regeneration and growing the tendons and stopping bleeding and removing swelling, and are used as adjuvant medicaments together; and the pinellia tuber and the crabshell are used for detoxifying and lowering adverse-rising qi, and are used as historical medicaments together. The medicaments have the effects of promoting blood circulation by removing blood stasis and growing the tendons and setting the bones. The medicament of the invention makes osteotylus form quickly, has the good treatment effect, simplified medicinal odors and low cost, solves the problems of various medicinal odors, high cost, serious gastrointestinal reactions and the like in the process of treating fractures and traumatic injury currently, and overcomes the defects of treating the fractures by using a mechanical method in western medicine. The clinical healing can be achieved after one month of the fracture, and the fracture can be healed totally for 2 to 3 months. The medicament has simplified medication and low cost, and is accepted by bone fracture patients in each level.
The present invention discloses an intravenous injection medicine for treating ischemic cardio-cerebrovascular diseases and a method for preparing the medicine. Red sage roots, chuanxiong rhizomes, immature astragalus roots, pueraria roots and safflowers are used as raw materials. The raw materials are respectively decocted, filtered, soaked in ethanol, filtered through washing and concentrated to obtain each concentrated solution according to different characteristics of the traditional Chinese medicines. Then, the concentrated solutions are mixed, and the pH value is adjusted. Oxidation resistant agents, solubilizers and adsorbing agents are added and mixed in proportion, and the intravenous injection medicine is obtained through the process steps of filling, sterilization, etc. The formula and the preparing method of the present invention are unique. The total effective rate of relieving symptoms of cardiac neuralgiain the clinical treatment is 100%, the effective rate of electrocardiograms is 95.28%, and the total effective rate of cerebrovascular diseases is 93.3%. After detected, hemorheology, nail wall circulation, blood pressure, etc. are all changed obviously.
BACKGROUND: Fabry disease (FD) and transthyretin cardiac amyloidosis (TTR CA) are cardiomyopathies with hypertrophic phenotype that share several features, including left atrial (LA) enlargement and dysfunction, but direct comparative data are lacking. Aim of the present study was to perform a comparative analysis of LA remodelling between the two diseases.
METHODS AND RESULTS: In this prospective study, a total of 114 patients (31 FD and 83 TTR CA) were included; all of them had left ventricular hypertrophy (LVH), defined as left ventricular (LV) wall thickness ≥ 12 mm. Despite similar degree of LVH, patients with TTR CA showed worse LV systolic and diastolic function. LA maximal volume index was not significantly different between the two groups (p = 0.084), while patients with TTR CA showed larger LA minimal volume index (p = 0.001). Moreover, all phases of LA mechanics were more impaired in the TTR CA group vs FD (reservoir: 6.9[4.2-15.5] vs 19.0[15.5-29.5], p < 0.001). After excluding patients with atrial fibrillation (AF), these differences remained clearly significant. In multivariable regression analyses, LA reservoir strain showed an independent correlation with TTR CA, controlling for demographic characteristics, AF and LV systolic and diastolic performance (p ≤ 0.001), whereas LV global longitudinal strain did not. Finally, among echocardiographic parameters, LA function demonstrated the highest accuracy in discriminating the two diseases.
CONCLUSIONS: TTR CA is characterized by a more advanced LA structural and functional remodelling in comparison to patients with FD and similar degree of LVH. The association between TTR CA and LA dysfunction remains consistent after adjustment for potential confounders.
A closure for dispensing one or more active agents into a container comprises a sealed or sealable chamber having a breakable wall and a hollow piston slidably mounted in a piston guide. Said hollow piston comprises an outer wall having an end in the chamber and at least one ventilation aperture. Said end has a cutting formation. Said hollow piston is slidable in the piston guide between a ventilation position in which the at least one ventilation aperture allows ventilation of the chamber and a sealed position in which the at least one ventilation aperture is sealed to prevent ventilation of the chamber and a deployed position in which the cutting formation has broken through at least a portion of the breakable wall. The outer wall has a retaining formation which engages with the piston guide to releasably resist sliding of the hollow piston between the ventilation position and the sealed position and the deployed position. The hollow piston may have an outer wall, and said outer wall has an end within the chamber, facing the breakable wall, wherein the cutting end has a first edge having a cutting formation and a gap in said cutting formation.
Provided is an implantable composite which includes a plurality of resorbable ceramic particles with or without a biodegradable polymer. The resorbable ceramic particles can be granules including carbonated hydroxyapatite and tricalcium phosphate in a ratio of 5:95 to 70:30. Some resorbable ceramic particles are granules, which include carbonated hydroxyapatite and β tricalcium phosphate in a ratio of 5:95 to 70:30. The resorbable ceramic particles have a particle size from about 0.4 to about 3.5 mm. The implantable composite is configured to tit at or near a bone defect as an autograft extender to promote bone growth. Methods of using the implantable composite are also provided.
PROBLEM TO BE SOLVED: To obtain a pollinosis-preventing medicine containing a cation surfactant. SOLUTION: This pollinosis-preventing medicine contains one or more kinds of cationic surfactants having each at least a guanidino group as a cationic group in the molecule and having a surface-activating ability as an active ingredient in an amount of >=0.01wt.% based on the whole amount of the composition. The compound includes hexadecylguanidine hydrochloride and oleylguanidine. The simultaneous use of a basic amino acid or its salt, choline or its derivative improves the effect. The cation surfactant well adsorbs pollens, or further breaks the outer skin of the pollen, acts also on the inner protoplasm to change the protoplasm, and denaturates an antigen itself causing the pollinosis. The action is capable of eliminating the harm of the pollen itself and thereby controlling the crisis of the pollinosis.  The pollinosis-preventing medicine is especially effective for the pollens of Cryptomeria japonica, Ambrosia artemisiifolia, Dactylis glomerata, Solidago serotina, Artemisia princeps, white cedar, etc.
Vortioxetine will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of vortioxetine can be lowered to 10 mg for tolerability reasons.
Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, IV 

Pediatric Patients: 10 mg/kg to 20 mg/kg, not to exceed 600 mg/day, IV 

Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.

###  Preparation of Solution for IV Infusion

Reconstitute the lyophilized powder by transferring 10 mL of sterile water for injection to a vial containing 600 mg of rifampin for injection. Swirl vial gently to completely dissolve the antibiotic. The reconstituted solution contains 60 mg rifampin per mL and is stable at room temperature for up to 30 hours. Prior to administration, withdraw from the reconstituted solution a volume equivalent to the amount of rifampin calculated to be administered and add to 500 mL of infusion medium. Mix well and infuse at a rate allowing for complete infusion within 3 hours. Alternatively, the amount of rifampin calculated to be administered may be added to 100 mL of infusion medium and infused in 30 minutes.

Dilutions in dextrose 5% for injection (D5W) are stable at room temperature for up to 8 hours and should be prepared and used within this time. Precipitation of rifampin from the infusion solution may occur beyond this time. Dilutions in normal saline are stable at room temperature for up to 6 hours and should be prepared and used within this time. Other infusion solutions are not recommended.

###  Incompatibilities

Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.
ADPKD patients with blood pressure above 130/85 are enrolled. The patients whose blood pressure is controlled under 130/85 by Candesartan alone are classified into group A.
Patients will be transferred from MDI to sensor-augmented pump (SAP) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
The invention provides a nucleoside hydrogel for preventing and/or delaying oral leukoplakia canceration and a preparation method and application thereof, belonging to the technical field of medicines. The nucleoside hydrogel is formed by cross-linking raw materials of guanosine, borate, alkali metal ions and tannic acid in a solvent. The DG-TA hydrogel integrating the carrier and the drug effect is successfully constructed on the basis of DG and TA through a boric acid diester bond. The hydrogel has good oxidation characteristic, can effectively prevent and/or delay oral leukoplakia canceration, and has excellent effect. Meanwhile, the hydrogel has excellent in-vivo degradation performance, good injectability and excellent skin adhesion performance; not only can inject and administer, but also can administer by smearing mode simultaneously, and the medicine is safer to use, and the effect is more excellent. In addition, the hydrogel is simple to prepare and has a good application prospect.
Packaged frozen cubes of  Cannabis  juice purée having decarboxylated cannabinoids are provided. First, raw  Cannabis  material is collected. Next, the  Cannabis  material is blended with water, fruit juice, or vegetable juice and thickening agent to form  Cannabis  juice purée. Next, the purée is poured into molds having an identical size and shape. Decarboxylated/non-decarboxylated high concentrate  Cannabis  extract or decarboxylated  Cannabis  infusion is added to the molds. Next, the tray is frozen to obtain frozen cubes of  Cannabis  juice purée. Next, the cubes are removed from the tray and are packaged in a vacuum sealed bag. A dispensary can store the package in a freezer until distribution. The package includes a label describing amounts and types of cannabinoids present in each cube. A consumer opens the package and deposits a desired amount of cubes into a blender along with other ingredients to form a beverage with non-decarboxylated cannabinoids.